![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2020
Richard, Yolande; Kemmerer, C. L.; Pernpeintner, V.; Ruschil, C.; Abdelhak, A.; Scholl, M.; Ziemann, U.; Krumbholz, M.; Hemmer, B. und Kowarik, M. C. 
ORCID: https://orcid.org/0000-0003-1389-5539
(2020):
Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
In: PLOS ONE 15(7), e0235449 [PDF, 1MB]
ORCID: https://orcid.org/0000-0003-1389-5539
(2020):
Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
In: PLOS ONE 15(7), e0235449 [PDF, 1MB]
2016
Stellmann, J.-P.; Krumbholz, M.; Friede, T.; Trebst, C. und Kleiter, I.
(2016):
Efficacy of immunotherapies and predictors of therapy response in neuromyelitis optica spectrum disorders: analysis of 397 treatment years from 150 patients.
In: Multiple Sclerosis Journal, Bd. 22: S. 406